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The biosynthesis of fusion-competent envelope glycoproteins (GPs) is a crucial step in productive viral infec-
tion. In this issue, Klaus et al. (2013) identify the cargo receptor endoplasmic reticulum (ER)-Golgi intermedi-
ate compartment 53 kDa protein (ERGIC-53) as a binding partner for viral GPs and a crucial cellular factor
required for infectious virus production.Over the past decades, several envel-
oped viruses of the arenavirus, filovi-
rus, hantavirus, and coronavirus families
have emerged as causative agents of
severe human disease with high mortality.
Considering the current lack of licensed
vaccines and the limited therapeutic
options at hand, the development of novel
antiviral drugs against these pathogens
is urgently needed. A major challenge
for the development of efficacious drugs
against emerging viruses is frequently
the limited molecular information avail-
able. However, as for all viruses, these
emerging enveloped viruses critically
depend on the molecular machinery of
the host cell for their multiplication. There-
fore, targeting cellular factors represents
a promising approach for therapeutic
intervention.
A crucial step in the multiplication of
enveloped viruses is the biosynthesis of
the fusion-competent envelope glycopro-
tein (GP) that decorates the virion surface
and mediates host cell attachment and
entry. Enveloped viruses hijack the host
cell’s secretory pathway for GP biosyn-
thesis. En route through the secretory
pathway, viral GPs are subject to
posttranslational modifications, includingN- and O-glycosylation and, in many
cases, proteolytic processing by cellular
proteases. While much has been learned
in the past years about the nature of these
modifications and their role in GP stability
and biological function, the specific
nature of the cellular factors implicated
in GP synthesis, transport, and matura-
tion is only partially understood. In this
issue of Cell Host & Microbe, Klaus et al.
(2013) sought to close this gap by
performing a broad proteomic screen to
identify cellular proteins that interact with
viral envelope GPs. Using the GPs of the
prototypic arenavirus lymphocytic chorio-
meningitis virus (LCMV) and the New
World hantavirus Andes (ANDV) as baits,
an unbiased screen was carried out, em-
ploying a pull-down approach, combined
with mass spectrometry analysis. The
screening results revealed complex
interaction patterns for both viral GPs,
including numerous candidate cellular
proteins. Despite remarkable differences
in their interactomes, both LCMV and
ANDV GPs were found to associate with
a set of common cellular proteins.
Among the candidate proteins present
in both sets, a mannose-specific mem-
brane lectin associated with the endo-plasmic reticulum (ER)-Golgi intermediate
compartment (ERGIC), ERGIC-53, was of
particular interest (Itin et al., 1996; Schwe-
izer et al., 1988). In mammalian cells,
the ERGIC is a system of tubulovesicular
membrane clusters located between the
rough ER and the Golgi. ER-derived cargo
traffics to ERGIC-53-positive compart-
ments, followed by a second vesicular
transport step toward the Golgi (Appenz-
eller-Herzog and Hauri, 2006). ERGIC-53
functions as a cargo receptor for the
transport of cellular glycoproteins from
the ER to the Golgi. A deficiency in
ERGIC-53 results in a selective defect in
glycoprotein secretion and, in humans,
manifests as combined factor V-factor
VIII deficiency (F5F8D), a rare, autosomal
recessive coagulation disorder charac-
terized by reduced levels of both coagu-
lation factors V and VIII (Neerman-Arbez
et al., 1999).
ERGIC-53 was found to specifically
interact with a broad spectrum of class I
viral fusion proteins derived from several
arenaviruses, hantaviruses, severe acute
respiratory syndrome (SARS) coronavi-
rus, influenza virus, and filoviruses. How-
ever, ERGIC-53 was unable to recognize
the G protein of vesicular stomatitis virus,ovember 13, 2013 ª2013 Elsevier Inc. 485
Figure 1. ERGIC-53 Is Crucial for the Formation of Infectious Arenavirus Particles
In uninfected cells, ERGIC-53 is largely confined to the ERGIC compartment and recycles from the Golgi. Early during infection with the arenavirus Junin virus
(JUNV), the GP precursor (GPC) associates with ERGIC-53, likely in an early compartment of the secretory pathway. The luminal carbohydrate recognition
domain (CRD) of ERGIC-53 is required for the interaction that seems otherwise distinct from the lectin-type binding of cellular cargo. Viral infection results in
trafficking of ERGIC-53 to the cell surface, where incorporation into budding virions occurs. The infectivity of progeny virions critically depends on the presence
of ERGIC-53 in their envelope.
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class of viral fusion proteins. This sug-
gests some specificity for class I viral
GPs, a notion that is supported by the
recently reported interaction of ERGIC-
53 with the envelope GP of HIV (Ja¨ger
et al., 2012). Remarkably, ERGIC-53 pref-
erentially associated with the immature
GP precursors, pinpointing early com-
partments of the secretory pathway as
sites of interaction (Figure 1). Employing
a comprehensive set of functional assays,
a strong case is made for a role of ERGIC-
53 in productive viral infection. Using a
combination of gene silencing by RNAi,
overexpression, and dominant-negative
(DN) mutants, evidence is provided that
ERGIC-53 is crucial for cell-to-cell propa-
gation of arenaviruses. These data are
complemented by impaired productive
infection in cells derived from patients
bearing an ERGIC-53 null mutation. As
anticipated from the interaction data,
the effect of ERGIC-53 mapped to the
viral GP. Notably, cellular ERGIC-53
was dispensable for viral entry, sug-
gesting a role in a later step of the viral
life cycle.
Formation and release (budding) of are-
navirus infectious progeny from infected
cells requires that assembled viral ribonu-486 Cell Host & Microbe 14, November 13, 20cleoprotein cores associate at the cell
surface with membranes enriched in viral
GPs. Considering the function of ERGIC-
53 as a cargo receptor implicated in
traffic from the ER to the Golgi, a possible
role in GP transport and maturation
was assessed. Rather unexpectedly, the
absence of ERGIC-53 had no effect on
the transport and posttranslational pro-
cessing of the viral GP. Characterization
of virus-like particles and authentic virions
produced in ERGIC-53-deficient cells re-
vealed efficient incorporation of GP into
particles that showed normal composition
but had markedly reduced infectivity. Un-
der normal conditions, ERGIC-53 does
not traffic beyond the cis-Golgi (Appenz-
eller-Herzog and Hauri, 2006). However,
viral infection resulted in the appearance
of ERGIC-53 at the cell surface where
virion budding occurs, indicating virus-
induced changes in trafficking of the
cargo receptor (Figure 1). ERGIC-53 was
found to be incorporated into budding
virions, and its presence was crucial for
infectivity. Initial characterization of the
interaction between arenavirus GP and
ERGIC-53 revealed that the carbohydrate
recognition domain was critical. However,
in contrast to ERGIC-53’s lectin-type
binding to cellular cargo, recognition of13 ª2013 Elsevier Inc.viral GP was independent of its capacity
to oligomerize or bind mannose and did
not require Ca2+ ions.
The discovery of a role for the cellular
cargo receptor ERGIC-53 in infectious
virus production is an exciting finding
that further illuminates the process of
enveloped virion maturation. The ability
of ERGIC-53 to recognize the precursors
of a wide variety of class I viral fusion
proteins derived from phylogenetically
distant viral families suggests an evolu-
tionarily conserved function. It will be of
interest to extend the screen to envel-
oped RNA viruses with class II fusion
proteins and enveloped DNA viruses.
The present study provides compelling
evidence for virus-induced changes in
ERGIC-53 trafficking, indicating that
viruses can reshape the subcellular distri-
butions of components of the secretory
pathway to optimize production of infec-
tious progeny. Previous studies revealed
that the cell’s unfolded protein response
(UPR) can induce ERGIC-53 trafficking
to the cell surface (Nyfeler et al., 2003),
and activation of the cellular UPR by are-
naviruses has recently been reported
(Pasqual et al., 2011). Since an ERGIC-
53 deficiency does not perturb the overall
structure and function of the secretory
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induced changes in ERGIC-53 trafficking
appear as rather subtle alternations in
the host cell.
The data at hand indicate a crucial role
of ERGIC-53 present in the virion mem-
brane for viral cell entry, whereas cellular
ERGIC-53 seems dispensable. A hall-
mark of arenaviruses is the selective
incorporation of processed mature GP
into nascent virions (Lenz et al., 2001).
Since ERGIC-53 associates specifically
with GP precursors, a direct interaction
of ERGIC-53 and mature GP at the level
of the virion membrane appears rather
unlikely. It will therefore be of great inter-
est to dissect the exact role of ERGIC-53
during the viral entry process. As pro-
posed by Klaus et al. (2013), ERGIC-53
may function as a structural component
of the virion, perhaps by acting as a cor-
eceptor required for virion attachment.
The requirement of ERGIC-53 for infec-
tivity of arenaviruses, coronaviruses, and
filoviruses would suggest a coreceptor
function in the context of a wide range
of cellular receptors and target cells.
Since receptor-mediated viral entry is a
complex process, the identification of
the specific entry step(s) that depend on
ERGIC-53 will be crucial. Suitable quanti-
tative assays to discern effects on virus-
cell binding from endocytosis and/or viral
fusion have been developed for many
viral systems of interest. Alternatively,ERGIC-53 may affect virus-cell attach-
ment indirectly by altering the oligomeri-
zation and/or geometry of GP at the
virion surface. Defining the specific steps
requiring ERGIC-53 may then facilitate a
search for viral and cellular binding part-
ners involved in the process. This will
provide deeper insight into the mecha-
nistic basis of the role of ERGIC-53 in
productive virus infection and shed light
on evolutionary conservation across virus
families.
Apart from its obvious interest from a
basic science point of view, ERGIC-53
also appears as an attractive cellular
target for therapeutic intervention. Hu-
mans bearing null mutations in ERGIC-
53 manifest with F5F8D, a relatively mild
disease (Neerman-Arbez et al., 1999),
suggesting that targeting this cellular
factor in a therapeutic approach may
have limited side effects. Additionally,
the characterization of the viral GP-
ERGIC-53 interaction performed by Klaus
et al. (2013) indicates differential recog-
nition of cellular cargo and viral GPs.
It is conceivable that small-molecule
screens for inhibitors of ERGIC-53-GP
binding may yield candidate compounds
that can perturb GP binding with lesser
effects on cellular cargo. Considering
the conservation of ERGIC-53 binding to
a wide range of viral GPs, such candi-
date inhibitors may show broad antiviral
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